Atypical Depression Clinical Trial
The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.
The general picture of depression is still that of the traditionally called endogenous type, which is also the form that was characterized extensively in clinical trials. Atypical depression with reversed vegetative signs, such as hyperphagia or hypersomnia, is traditionalla neglected, demonstrated by the fact that in the most widely used depression scales, such as the Hamilton Depression Scale, melancholic symptoms have a specific weight, while, by contrast, reversed vegetative signs are not included. This etablishes a tendency to underestimate the severity of atypical depression. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00610506 -
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
|
Phase 3 | |
Completed |
NCT00296699 -
A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression
|
Phase 4 | |
Completed |
NCT00215176 -
Modafinil for Atypical Depression
|
Phase 2/Phase 3 | |
Completed |
NCT00477854 -
Effects of Chromium Picolinate on Food Intake
|
N/A |